Enlivex Therapeutics (ENLV) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ENLV Enlivex Therapeutics

Watchlist

1.310
+0.010+0.77%

Trading Dec 4 15:13 ET

28.81MMarket Cap-1336P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
BenzingaDec 3 09:36 ET
Express News | Elivex Therapeutics Shares Are Trading Higher After the Company Announced Interim Efficacy Data Showing Statistical Significance and Marked Improvements for Its Allocetra Trial
BenzingaDec 3 09:14 ET
Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis
BenzingaDec 3 08:32 ET
Express News | Enlivex Therapeutics Ltd - Interim Results Show Statistically Significant Improvements in Pain and Functionality
ReutersDec 3 08:30 ET
Enlivex Therapeutics Faces Financial Challenges Amid Losses
TipRanksNov 29 16:58 ET
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
AccesswireNov 26 10:15 ET

Comments

Jaguar8

21 hours ago

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

Jaguar8

Dec 3 07:34

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday, 3rd December at 8:30 am
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ tri...

Jaguar8

Nov 20 07:05

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Adopts Bitcoin Treasury Reserve Strategy

Trytosaveabit

Nov 20 07:03

News

$Enlivex Therapeutics (ENLV.US)$ Benzinga· 1 min ago
Enlivex Board Approves Purchase Of Up To $1M Of Bitcoin

Jaguar8

Nov 14 07:03

NEWS

$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Enlivex Therapeutics has initiated a Phase I clinical trial evaluating Allocetra™ in patients with psoriatic arthritis. The first patient has completed dosing and initial follow-up with no safety concerns reported. The trial aims to recruit six patients who haven't responded adequately to conventional therapies. The study wi...

Heat List

Overall

No Data

Investment Theme

Top Gainers Yesterday

Intraday-1.34%